LLY Eli Lilly and Company

108.47
+0.18  (+0%)
Previous Close 108.29
Open 108.3
Price To Book 42.54
Market Cap 105,306,024,252
Shares 970,830,868
Volume 4,405,151
Short Ratio 2.62
Av. Daily Volume 4,160,064

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met primary endpoint - February 4, 2019. Data to be presented 2019.
Baricitinib
Atopic dermatitis
Phase 1/2 updated data noted ORR of 59% - October 6, 2018.
LOXO-292
RET-fusion non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other tumors
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
FDA approval announced September 27, 2018.
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
NDA filing announced November 14, 2018. Estimated PDUFA date November 13, 2019.
Lasmiditan - SPARTAN
Migraine
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 trial met primary endpoint - noted October 2, 2018.
Ultra rapid insulin
Diabetes
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Data from trial April 18, 2019 met 2/3 primary endpoints in 5mg arm but failed to meet endpoints in 2.5mg arm.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 PFS data met primary endpoint but overall survival not improved. Will not seek regulatory approval.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 trial met primary endpoints - September 5, 2018.
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 data due 2019.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 data due 2019.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Approval announced February 26, 2018.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Approved October 4, 2017.
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
Phase 3 data released October 10, 2017 - primary endpoint not met.
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Approval announced December 1, 2017.
Taltz
Psoriatic Arthritis
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
FDA Approval announced November 26, 2018.
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.
Phase 3 trial met primary endpoint - noted June 25, 2018.
Empagliflozin
Type 1 Diabetes
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
FDA approval announced May 13, 2019.
Ramucirumab REACH-2
Hepatocellular Carcinoma
Phase 3 PFS primary endpoint met - March 12, 2019.
Ramucirumab
Non-small cell lung cancer
Phase 3 trial met primary endpoint - noted June 28, 2018.
Ixekizumab
Axial Spondyloarthritis
Phase 3 trial met primary endpoint - July 19, 2018.
Tradjenta (linagliptin) - CARMELINA CV outcomes
Type 2 Diabetes
FDA Approval announced June 4, 2019.
Galcanezumab
Cluster headache
Phase 3 top-line data due 2021.
Mirikizumab (LY3074828)
Ulcerative Colitis
Phase 3 data noted 12% reduction in MACE - June 9, 2019.
Trulicity REWIND CV outcomes
Type 2 diabetes
Phase 3 trial met primary endpoint of non-inferiority.
Tradjenta (linagliptin) - CAROLINA CV outcomes
Type 2 Diabetes
Phase 2 data due 2020.
DONANEMAB N3pG Antipody
Alzheimer's disease
Phase 3 data due 2021.
Abemaciclib (Verzenio) - MonarchE
Breast cancer - adjuvant
Phase 3 data due 2020.
Mirikizumab
Psoriasis
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 top-line data due 2020.
AM0010 (PEG-IL-10) - Sequoia
Pancreatic ductal adenocarcinoma (PDAC)
Phase 2 top-line data due late 2019.
AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1
Non-small cell lung cancer (NSCLC)
Phase 2 top-line data due 2H 2019.
AM0010 (pegilodecakin) and Nivolumab - Cypress 2
Non-small cell lung cancer (NSCLC)
Phase 1/2 initiation announced December 21, 2018.
LOXO-305
Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphomas (NHL)
Phase 3 data released January 18, 2018 did not meet primary endpoint. FDA had already awarded accelerated approval.
LARTRUVO (olaratumab)
Soft tissue sarcoma (STS)
Phase 3 data released April 22, 2019 met primary endpoint. Regulatory filing planned later in 2019.
Taltz (Ixekizumab)
Non-radiographic axial spondyloarthritis
Phase 3 data due 2019.
Taltz (Ixekizumab)
Psoriasis
Phase 3 trial to be initiated 2H 2019.
Tirzepatide
Type 2 Diabetes
Phase 3 trials to be initiated by YE 2019 with data due 2021.
Tirzepatide - Surpass
Type 2 Diabetes
Phase 3 trial to be initiated later in 2019.
Mirikizumab
Crohn's disease
Phase 3 data due 2019.
Dulaglutide
Type 2 diabetes
NDA acceptance announced June 4, 2019. PDUFA date not announced. Estimate April 3, 2020 using 10-month timeline.
Empagliflozin, linagliptin and metformin - triple combo
Type 2 Diabetes
Phase 3 trial met primary and key secondary endpoints - December 17, 2018.
Taltz (Ixekizumab) and adalimumab
Psoriatic Arthritis

Latest News

  1. Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
  2. Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
  3. Health Care stocks help lead Wall Street rally
  4. Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug
  5. Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
  6. AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
  7. Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
  8. 4 Drug Stocks Getting Smashed
  9. 4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
  10. The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices
  11. UPDATE 1-Eli Lilly's bio-medicines head to leave next month
  12. Lilly Announces Changes in Senior Leadership
  13. New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache
  14. Stocks - Health Insurers Drive Dow to New Record at Opening
  15. Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific
  16. Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment
  17. The 10 Biggest Healthcare Stocks
  18. Court Ruling Topples Trump Order, No Price Display in TV Ads
  19. Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement
  20. Judge rules against Trump on drug pricing disclosures